Table 4. Factors associated with AFP decrease between AFP reduction and non-reduction cohorts.
| Variable | No decrease in AFP (n = 11) | Decrease in AFP (n = 47) | p |
| Baseline AFP, ng/mL | 3.5 (2.4–6.3) | 8.4 (4.8–16.5) | 0.001 |
| Viral load | 2380000 (1335000–3425000) | 1200000 (394000–3712500) | 0.917 |
| Platelet count, 103/μL | 60.5 (47.2–77.8) | 104 (67–145) | 0.009 |
| Albumin, g/dL | 3.4 (3.2–3.7) | 3.7 (3.3–4.2) | 0.106 |
| INR | 1.2 (1.2–1.3) | 1.1 (1.1–1.2) | 0.103 |
| AST, U/L | 44.5 (32.5–54.5) | 66 (40.2–95.8) | 0.036 |
| ALT, U/L | 31.5 (25–45) | 55.5 (35–76.8) | 0.028 |
| Total bilirubin, mg/dL | 2 (1.7–2.8) | 0.8 (0.6–1.4) | 0.018 |
| Serum creatinine, mg/dL | 0.8 (0.7–0.9) | 0.9 (0.7–1) | 0.412 |
| Alkaline phosphatase, U/L | 89 (81.8–115.2) | 104.5 (76–155.8) | 0.473 |
| Hemoglobin, g/dL | 13.2 (12.4–13.9) | 13.1 (11.9–14.1) | 0.946 |
| MELD | 12.1 (10–13.2) | 9.7 (7.5–11.4) | 0.085 |
| FIB4 | 5.7 (5.1–10.3) | 6.1 (3.3–10.1) | 0.462 |
| APRI | 1.3 (1.2–2.7) | 1.6 (0.8–3.7) | 0.76 |
| Sodium | 138.5 (134.2–139.8) | 139.5 (137.8–142) | 0.082 |
Abbreviations: AFP, alpha-fetoprotein; INR, international normalized ratio; AST, aspartate transaminase; ALT, alanine transaminase; MELD, model for end-stage liver disease; FIB4, fibrosis-4; APRI, AST to platelet ratio index.